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ABSTRACT
Introduction: The majority of stage III patients with
non-small cell lung cancer (NSCLC) are unsuitable for
concurrent chemoradiotherapy, the non-surgical gold
standard of care. As the alternative treatment options of
sequential chemoradiotherapy and radiotherapy alone are
associated with high local failure rates, various
intensification strategies have been employed. There is
evidence to suggest that altered fractionation using
hyperfractionation, acceleration, dose escalation, and
individualisation may be of benefit. The MAASTRO group
have pioneered the concept of ‘isotoxic’ radiotherapy
allowing for individualised dose escalation using
hyperfractionated accelerated radiotherapy based on
predefined normal tissue constraints. This study aims to
evaluate whether delivering isotoxic radiotherapy using
intensity modulated radiotherapy (IMRT) is achievable.
Methods and analysis: Isotoxic IMRT is a multicentre
feasibility study. From June 2014, a total of 35 patients
from 7 UK centres, with a proven histological or
cytological diagnosis of inoperable NSCLC, unsuitable for
concurrent chemoradiotherapy will be recruited. A
minimum of 2 cycles of induction chemotherapy is
mandated before starting isotoxic radiotherapy. The dose
of radiation will be increased until one or more of the
organs at risk tolerance or the maximum dose of 79.2 Gy
is reached. The primary end point is feasibility, with
accrual rates, local control and overall survival our
secondary end points. Patients will be followed up for
5 years.
Ethics and dissemination: The study has received
ethical approval (REC reference: 13/NW/0480) from the
National Research Ethics Service (NRES) Committee
North West—Greater Manchester South. The trial is
conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice (GCP). The trial results will be
published in a peer-reviewed journal and presented
internationally.
Trial registration number: NCT01836692; Pre-results.
INTRODUCTION
Lung cancer is the leading cause of cancer
mortality worldwide1 with approximately
40 000 new cases diagnosed annually in the
UK. Of these cases 34 000 will present with
non-small cell lung cancer (NSCLC) and
one-third (∼12 000) of patients with NSCLC
will present with locally advanced (stage III)
disease. The 5-year survival from lung cancer in
the UK has changed little (from 3% to 8%)
over the past 60 years, with progress lagging sig-
niﬁcantly behind other common cancers.
The 5-year survival of stage III NSCLC with
current standard treatment is approximately
10–15% highlighting a real urgency to
improve outcome for these patients.
Radiotherapy (RT), alone or combined
with chemotherapy, plays a major therapeutic
role in the treatment of stage III NSCLC.
Despite this, most patients still progress locally
and at sites of distant spread. Concurrent che-
moradiotherapy (chemotherapy and RT given
at the same time; CTRT) is the standard of
care in stage III NSCLC2 with median survival
rates of approximately 21 months. However,
the majority of patients are not suitable for
this treatment based on poor performance
status (PS) and comorbidities.3 In a recent
UK national survey of CTRT practice, the
majority of clinical oncologists estimated
that <30% of patients with stage III NSCLC
were suitable for concurrent CTRT.4 The
Strengths and limitations of this study
▪ Radiotherapy delivered using advanced techni-
ques, including intensity modulated radiotherapy
(IMRT), 4D-CT and image-guided radiotherapy
(IGRT) in all patients.
▪ Robust quality assurance (QA) programme.
▪ Multicentre study.
▪ Single arm study.
▪ Heterogeneity of the stage III patient group.
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alternative treatment offered to patients who are not suit-
able for concurrent CTRT is sequential CTRT (chemo-
therapy given prior to RT), but local control and survival
rates are inferior compared with concurrent CTRT.2 As
the majority of patients with stage III NSCLC cannot be
treated concurrently, strategies to improve outcome in
this large group of patients treated sequentially is vital.
Local control with current RT doses delivered with
standard three-dimensional conformal RT (3D-CRT) is
poor with local progression-free survival rates of about
30%. However, recent data has shown that improved
local control in lung cancer can lead to improvement in
survival.2 A meta-analysis of concurrent versus sequential
CTRT in locally advanced NSCLC based on individual
patient data demonstrated that although concurrent
treatment decreases locoregional progression (HR=0.77;
p=0.01); its effect is not different from that of sequential
treatment on distant progression (HR=1.04; p=0.69).2
The decrease in locoregional progression translated into
a signiﬁcant survival beneﬁt in favour of concurrent
CTRT (HR, 0.84; 95% CI 0.74 to 0.95; p=0.004), with an
absolute beneﬁt of 5.7% at 3 years and 4.5% at 5 years.
We are now accelerating into an era of personalised
medicine for the systemic treatment of NSCLC. However,
to date, ﬁxed doses of radiation are still delivered to
patients, not taking into account volume of disease, stage
of disease (IIIa vs IIIb) or anatomical location within the
thorax. Stage III NSCLC is a heterogeneous disease and
there is a need to move away from a ‘one-size-ﬁts-all’
approach to more personalised radiation treatments. The
concept of isotoxic RT was recently introduced allowing
the radiation dose prescription to the tumour to be tai-
lored based on normal tissue constraints.5 6
A strategy to improve local control is to escalate the
dose of radiation delivered to the tumour. Martel et al7
demonstrated a clear dose–response relationship in
NSCLC, with 84 Gy using conventional fractionation
required to achieve 50% probability of tumour control
at 3 years. Subsequently we have learnt from the stereo-
tactic body RT studies in NSCLC that biologically effect-
ive dose (BED) in excess of 100 Gy are necessary to
achieve >90% local control rates.8
However, a recent Radiation Therapy Oncology Group
(RTOG) phase III study that randomised patients
between 60 Gy in 30 daily fractions and 74 Gy in 37 daily
fractions has failed to demonstrate a survival advantage
for the high-dose arm indicating that dose escalation
using a conventional fractionation resulting in increased
overall treatment time is not the way forward in this
disease. The failure of the high-dose arm was likely
multifactorial and in addition to prolonged overall treat-
ment time may have resulted from a combination of
poorer treatment delivery with less patients receiving
concurrent chemotherapy, reduced compliance to RT,
QA issues and unreported treatment toxicity.9 Following
the presentation of RTOG 0617 a dose of 60 Gy biologic-
ally equivalent dose in 2 Gy fractions (EQD2) is consid-
ered to be standard in patients with stage III NSCLC.10
Accelerated hyperfractionation has been studied in an
attempt to reduce the overall treatment time and coun-
teract repopulation in lung cancer. In the national con-
tinuous hyperfractionated accelerated radiotherapy
(CHART) study there was a staggering 24% reduction in
the relative risk of death, which is equivalent to an abso-
lute improvement in 2-year survival of 9% with hyper-
fractionated accelerated RT (54 Gy in 36 fractions over
12 days) compared with conventional RT (60 Gy in 30
fractions over 6 weeks).11 Despite CHART showing this
signiﬁcant beneﬁt, it has not become standard practice
in the UK. First, a large percentage of patients included
had stage I–II disease (36%) who would now be consid-
ered for surgery or stereotactic body radiotherapy
(SABR), and second, the control arm would not be con-
sidered current standard of care since chemotherapy
was not delivered with RT (either sequentially or concur-
rently). Subsequently an individual patient data
meta-analysis of 2000 patients from 10 trials, demon-
strated that modiﬁed fractionation (acceleration, hyper-
fractionation or both) improves overall survival as
compared with conventional fractionation in NSCLC
resulting in an absolute beneﬁt of 3% at 5 years.12
Intensity modulated radiotherapy (IMRT) modulates
the intensity proﬁle of the radiation delivered to the
patient allowing improved targeting of the radiation
dose. This technique allows a decrease in the mean lung
dose (MLD), V20 (percentage volume of total lung
receiving ≥20 Gy), and maximal spinal cord dose. As a
result the dose delivered to the tumour can be escalated
while keeping the dose to the normal tissue within toler-
ance.13 Although IMRT is becoming standard for the
treatment of lung cancer in large international academic
centres, in the UK implementation of IMRT is currently
poor. In September 2010 Cancer Research UK reported
that UK RT practice is ‘lagging behind’ with only 7% of
patients receiving IMRT compared with 20% in Europe.
The MAASTRO group have pioneered the concept of
‘isotoxic RT’ allowing for individualised dose escalation
using hyperfractionated accelerated RT based on prede-
ﬁned MLD and spinal cord dose in stage I–III patients.6
They have shown with 3D-CRT delivered two times a day
over 4 weeks that increasing the radiation dose to pre-
speciﬁed normal tissue dose constraints could lead to
increased tumour control probability with the same
normal tissue complication probability. In the stage III
group of patients the mean dose delivered was 61.2 Gy
(ie, 72.2 Gy BED10 and 60.2 Gy EQD2), range 50.4–
79.2 Gy (ie, 59.5 Gy BED10 and 49.6 Gy EQD2 –93.5 Gy
BED10 and 77.9 Gy EQD2) and <10% of patients
received the maximum dose as per protocol of 79.2 Gy
in 39 fractions two times a day with 3D-CRT (ie, 95.3 Gy
BED10, 79.4 Gy EQD2). The survival rates of stage III
patients in this study, all of whom were treated with
sequential CTRT, were comparable to the results
expected with concurrent CTRT with acceptable acute
and late toxicity. It is important to note that IMRT was
not used in the MAASTRO study. Our in-house planning
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study, has conﬁrmed the use of IMRT could allow further
individual dose escalation in this group of patients, which
may ultimately translate into improved survival.14
METHODS AND ANALYSIS
The Isotoxic IMRT study is a non-blinded multicentre
feasibility study. The study is sponsored by The Christie
NHS Foundation Trust* and coordinated by the Manchester
Academic Health Science Centre Trial Co-ordination Unit
(MAHSC-CTU) based at The Christie NHS Foundation
Trust. Data management is undertaken by the MAHSC-
CTU. The trial is registered on the clinicaltrials.gov data-
base (NCT01836692) and jointly funded by Cancer
Research UK’s Clinical Trials Awards and Advisory
Committee (CTAAC) and the British Lung Foundation
(BLF). The study is included in the National Institute for
Health Research (NIHR) Clinical Research Network port-
folio (ID: 14937). The trial is conducted in accordance
with the Declaration of Helsinki and Good Clinical
Practice (GCP).
The primary research question is to evaluate the feasi-
bility of delivering isotoxic RT using IMRT and hyperfrac-
tionated accelerated RT in patients with stage III NSCLC
unsuitable for concurrent CTRT.
The secondary research questions are:
1. Estimate the feasibility of delivering lung isotoxic
IMRT
2. Estimate the proportion of patients with acute grade
3+ non-haematological toxicity
3. Estimate late toxicity
4. Estimate local control and overall survival
5. Develop a robust QA process for lung IMRT
Setting
In total, 35 patients with a histological or cytological
proven diagnosis of NSCLC will be recruited from seven UK
centres: Addenbrookes (Cambridge), Beatson (Glasgow),
The Christie NHS Foundation Trust (Manchester), Royal
Marsden (London), Northern Ireland Cancer Centre
(Belfast), Weston Park (Shefﬁeld), St James’s Hospital
(Leeds). The study started recruitment in June 2014.
Patients with stage III NSCLC, PS 0–2, not suitable for
concurrent CTRT, will be treated with individualised
doses of radiation based on prespeciﬁed normal tissue
doses (spinal cord, brachial plexus, lung tissue, heart
and great vessels/proximal bronchial tree table 1). The
study ﬂow diagram is shown in ﬁgure 1.
Participant screening and selection
Patients have been deemed inoperable by the lung
multidisciplinary team (MDT) and suitable for sequen-
tial CTRT. Eligible patients are invited to participate and
provided with a patient information sheet (see online
supplementary appendix 1). Patients are only registered
into the Isotoxic IMRT study once. Mandatory investiga-
tions prior to registration included: a Contrasted CT
scan of the thorax and upper abdomen (within 4 weeks
prior to registration), Contrast-enhanced CT (or MRI)
brain scan (within 4 weeks prior to registration if
patients have not had imaging of the brain prior to
starting induction chemotherapy), ﬂuorodeoxyglucose-
positron emission tomography (FDG-PET) CT within
4 weeks prior to registration if patients have not had a
PET-CT prior to starting induction chemotherapy and
lung function tests.
Inclusion criteria
▸ Histologically or cytologically conﬁrmed NSCLC
▸ Inoperable stage III disease (T3N1-3, any T4, any
N2-3) conﬁrmed by PET scanning, mediastinoscopy
or thoracoscopy
▸ Patients treated with at least two cycles of platinum-
based induction chemotherapy and able to start RT
within 5 weeks of the last cycle of chemotherapy
▸ Tumour judged inoperable by a lung MDT
▸ Age ≥18, no upper age limit
▸ PS—Eastern Cooperative Oncology Group (ECOG)
scale 0–2. Patients with PS 2 whose general condition
is explained by disease can be included at the discre-
tion of the local investigator. Patients with PS 2 as a
result of comorbid conditions will be excluded
▸ Patient considered suitable for radical RT
▸ Tumour that can be encompassed within a radical RT
treatment volume (MLD expected to be ≤20 Gy).
Exclusion criteria
▸ Patients suitable for standard concurrent CTRT
▸ Patients only suitable for radical RT alone
Informed consent
Eligibility to participate is conﬁrmed by a clinician prior
to consent being taken. Patients are given at least 24 h
to consider the patient information sheet and time to
ask questions prior to written informed consent being
taken by a trial doctor. The consent form can be viewed
in online supplementary appendix 2.
Table 1 Prespecified normal tissue doses (specified to a
volume of 1 cc)
Organ at risk Prespecified normal tissue doses
Brachial plexus Maximum dose=EQD2≤66 Gy
Heart Maximum dose=EQD2≤76 Gy
Mean dose ≤46 Gy
Lung Mean lung dose (lung—GTV) ≤20 Gy
Mediastinal
envelope*
Maximum dose=EQD2≤76 Gy
Spinal canal PRV Maximum dose=EQD2≤50 Gy
*Including: heart, proximal bronchial tree, trachea, oesophagus
and the blood vessels in the upper mediastinum.
EQD2, equivalent dose in 2 Gy fractions; GTV, gross tumour
volume; PRV, planning organ at risk volume.
*Research & Development, Wilmslow Road, Manchester, M20 4BX, UK.
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Registration
Registration into this study takes place after completion
of chemotherapy. Once a patient is deemed eligible for
the study and has consented to participate, the
MAHSC-CTU will allocate a participant identiﬁcation
number by telephone and conﬁrm enrolment by email.
Standard care
In patients with inoperable stage III NSCLC who are
unsuitable for concurrent CTRT, sequential CTRT is the
standard of care. While on study participants will not
co-enrol in other clinical trials offering therapeutic inter-
vention. Patients can withdraw from the trial at any time
without any effect on clinical care.
RT intervention and planning
4D-CT scanning is mandatory to account for tumour
motion during the breathing cycle. The use of intraven-
ous contrast is mandated (patients with a medical
contraindication should not be included in the study).
The whole thorax (cricoid to L2) should be covered to
allow dose volume histograms to be calculated for the
lung, heart, spinal cord, brachial plexus, great vessels,
proximal bronchial tree and the oesophagus. RT should
be started within 3 weeks of 4D-CT planning scan date.
▸ The motion adapted gross tumour volume (GTV) is
deﬁned as identiﬁable tumour and involved lymph
nodes.
▸ The clinical target volume (CTV) will encompass
regions at risk of microscopic extension.
▸ The CTV comprises the GTV with a 5 mm margin of
radiologically normal tissue in all directions.
▸ CTV to planning target volume (PTV) expansion
takes into account patient set-up uncertainties.
Tumour motion has been taken into account within
the ‘motion-adapted GTV’.
▸ The PTV comprises the CTV with a 0.9 cm margin
superiorly and inferiorly, and 0.7 cm margin laterally.
▸ Editing of the PTV is not permitted.
Prescribed dose and fractionation
RT doses will be individually escalated until one or more
of the organs at risk (OAR) tolerance or the maximum
dose of 79.2 Gy is reached. At least 95% of the PTV
should receive 90% (ideally 95%) of the prescribed dose
and the mean dose to the CTV should be 100%.
Hotspots should not exceed 107% of the prescribed
dose within a 1 cc volume. IMRT will be delivered two
times a day on consecutive weekdays, at 1.8 Gy per frac-
tion, with a minimum 6 h interval between fractions. A
maximum of 44 fractions will be delivered for the
maximum dose of 79.2 Gy. The overall treatment time
should include as few weekends as possible.
Prescribing the treatment using the mean dose to the
PTV for lung tumours can be problematic. In certain
situations low-density lung tissue at the edge of the PTV
can lead to an exaggerated increase in the monitor units
needed to achieve the necessary mean dose. For this
reason it is suggested that the mean dose will be pre-
scribed to the CTV.
Dosimetry/dose specifications
Treatment planning will be with inverse planned IMRT.
This optimisation must be performed by an experienced
dosimetrist/physicist in lung planning.
Figure 1 Trial schema. BD, two times a day; CBCT, Cone beam computer tomography; CTRT, chemoradiotherapy; ECOG,
Eastern Cooperative Oncology Group; IMRT, intensity modulated radiotherapy; NSCLC, non-small cell lung cancer; PET, positron
emission tomography; PTFs, pulmonary function tests; RT, radiotherapy.
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The use of volumetric modulated arc therapy
(VMAT)/RapidArc/tomotherapy/ﬁxed-beam IMRT is
allowed in this study. If ﬁxed-beam IMRT is used, it is sug-
gested that ﬁve or more ﬁelds should be used to avoid
creating hot-spots in normal tissue and ensure optimal
dose distribution. The use of these techniques facilitate
the mandatory PTV coverage of D95 ≥90% (ideally 95%)
of the prescribed dose and a 1 cc maximum <107%.
Patients are treated with individualised doses of radi-
ation based on prespeciﬁed normal tissue constraints
(spinal cord, brachial plexus, lung tissue, heart and
great vessels/proximal bronchial tree). RT is delivered
two times a day over a maximum period of 4.5 weeks
using IMRT and the dose of radiation is increased until
one or more of the OAR tolerance or the maximum
dose of 79.2 Gy is reached.
Follow-up
Patients are followed up for 5 years post-treatment
(4 monthly in years 1 and 2, 6 monthly from years 2–5).
A late toxicity assessment will be performed at each visit.
Statistical considerations
This feasibility study will be two-stage (with early stop-
ping rules) using the design of Bryant and Day with
85% power and 15% signiﬁcance level for both comple-
tion and acute radiation pneumonitis rates. Using the
design of Bryant and Day15 to combine an acceptable
rate of 90% and unacceptable rate of 70% of patients
receiving >60 Gy EQD2 and an acceptable rate of grade
3+ acute radiation pneumonitis of 8.5% and unaccept-
able rate of 22.5%, 35 patients will be recruited from
seven centres over 2 years.
Stage I: Enrol 11 patients stop if;
1. Less than 7 of 11 patients can be planned to a dose
>60 Gy EQD2
2. More than 3 of 11 patients experience grade 3+
acute radiation pneumonitis.
If three patients have experienced grade 3+ acute radi-
ation pneumonitis before enrolment of the last patient
in stage I, recruitment to stage II would only start when
the last patient enrolled in stage I has reached 3 months
follow-up. This would be done to ensure the absence of
acute radiation pneumonitis in the fourth patient
treated before proceeding to stage II.
Stage II: Enrol a further 24 patients, totalling 35, con-
clude a negative study if;
1. Less than 27 of 35 patients can be planned to a dose
>60 Gy EQD2
2. More than 6 of 35 patients experience grade 3+
acute radiation pneumonitis.
There is no planned interim analysis. The study will
stop after stage I if the conditions aforementioned are
met.
Primary analysis
Total radiation dose, proportion of patients receiving
>60 Gy EQD2 to those receiving ≤60 Gy EQD2 and the
reason why isotoxic IMRT≤60 Gy EQD2 will be
reported.
Secondary analysis
Percentage of patients who are deemed suitable to
receive isotoxic IMRT, withdrawal rates, recruitment
rates, incidence of toxicity, incidence of serious adverse
events (SAEs), estimation of local control and estimation
of overall survival (calculated from date of registration)
will be reported.
Changes to the protocol after the start of the trial
The trial details documented here are consistent with
Isotoxic IMRT study protocol V.5.0 (dated: 3 December
2013). There have not been any signiﬁcant changes to
the protocol after the start of the study.
End of the trial
The study will close 5 years after the last patient com-
pletes RT treatment. The chief investigator and/or the
trial management group (TMG) have the right at any
time to terminate the study for clinical or administrative
reasons. The end of the study will be reported to the
REC and Regulatory Authority (where applicable)
within the required timeframes.
QA programme
The trial is subject to a RT QA programme which is tai-
lored to the technical requirements of lung IMRT. This
programme will facilitate an audit of UK lung IMRT
practice and dosimetric accuracy of delivery, as well as
providing a standardised framework for implementation
of lung IMRT in participating centres. The QA pro-
gramme for the study is coordinated by the National
Cancer Research Institute (NCRI) Radiotherapy Trials
QA (RTTQA) Group. The details of the programme can
be found at the RTTQA website, http://www.rttrialsqa.
org.uk.
As part of the pretrial QA, sites were asked to complete
the following:
▸ RTTQA facility questionnaire.
▸ Outline a benchmark case, delineating the OAR on
the CT data set provided according to the study spe-
ciﬁc isotoxic IMRT atlas.
▸ Plan a benchmark case according to the trial protocol
on the predelinated CT (OAR’s, GTV, CTV and
PTV).
▸ The ﬁrst patient from each centre is reviewed before
that centre recruits a second patient. If there are any
problems with the ﬁrst patient a prospective case
review is mandated for the second patient.
▸ All RT plans are subject to review (retrospectively) by
the Mount Vernon NCRI RTTQA Group to ensure
adherence to the trials RT planning and delivery
protocol.
▸ Finally, a site visit and complex treatment dosimetry
check is carried out to review participating centres’
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4D-CT and treatment veriﬁcation processes and the
RTTQA lung IMRT dosimetry audit.
End of the trial
The trial will end once 35 patients have been recruited
and all patients have completed 6 months follow-up or
have died, whichever is sooner.
ETHICS AND DISSEMINATION
Safety reporting
Data is collected at each trial visit regarding any SAEs
(as deﬁned by GCP). All SAEs causally related to the RT
treatment are reported to the MAHSC-CTU and fol-
lowed until they resolve or stabilise. Acute and late radi-
ation toxicities continue to be recorded at each
follow-up visit (according to the CTCAE V.4.0 grading
system).
Trial monitoring and oversight
Formal on site data monitoring activities are performed
as part of the Isotoxic IMRT study.
As this is a feasibility study data is not reviewed by an
independent data monitoring committee, however,
individual patient and treatment experiences are dis-
cussed at the regular TMG meetings. The TMG coordi-
nates and manages the trial’s day-to-day activities. The
TMG is comprised of health professionals, a patient
representative and members of the direct study team,
including the principal investigators from each partici-
pating site.
Dissemination
Data from all centres will be analysed together and pub-
lished promptly. Individual participants may not publish
data concerning their patients that are directly relevant
to questions posed by the trial until the TMG has pub-
lished its report. The TMG will form the basis of the
Writing Committee and advise on the nature of publica-
tions. The trial will be publicised at regional and
national conferences. The ﬁnal results will be presented
at scientiﬁc meetings and published in a peer-reviewed
journal (authorship will be according to the journal’s
guidelines). In addition a lay summary of the results will
be produced for interested parties for example, Cancer
Research UK and BLF.
Trial status
The ﬁrst patient was registered in June 2014 and recruit-
ment continues to stage II of the study. The study com-
pleted recruitment in March 2016. The Isotoxic IMRT
trial along with three other phase I/II trials of
dose-escalated sequential CTRT, will be compared with a
UK standard sequential CTRT regime (55 Gy in 20 frac-
tions) using state-of-the art RT in a randomised phase II
trial. As it would be impossible to test all schedules in
phase III study it was decided to proceed with a com-
bined randomised phase II screening/“pick the winner”
approach to select one schedule for further testing in a
randomised phase III study.
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